Tobias Carlisle, Founder & Portfolio Manager at The Acquirers Fund, joins The Final Round to discuss his thoughts on the technology sector and whether it makes sense to invest into FAANG names amid such a volatile market. ...
(Bloomberg) -- Manhattan’s 1290 Sixth Avenue and San Francisco’s 555 California Street are outliers in President Donald Trump’s real-estate portfolio. His name doesn’t appear in big letters there. Trump owns only 30% of them. His company doesn’t have a management role.Yet without fanfare, the two office towers are also among the Trump Organization’s most lucrative assets, together generating tens of millions in cash flow each year, according to a Bloomberg analysis. Now the properties could propel the most lucrative real estate deal involving Trump’s company during tenure in the White House.Vornado Realty Trust, which holds the remaining 70% in the buildings, said this week it’s seeking to recapitalize them. People familiar with the matter said Vornado is looking to sell the high-rises and would lead the effort, meaning Trump’s family would be a step removed from talks. The Trump Organization is likely to sell its stakes as part of a deal,...
Stocks closed out Friday’s session sharply lower after Texas and Florida reversed their reopening processes and closed bars and limited restaurant capacity following surges in coronavirus cases. Each of the three major indices fell more than 2%, and the S&P 500 dropped to its lowest level in two weeks....
Recent headlines were saturated with the alarming uptick of new coronavirus cases in several states. Accordingly, the stock market experienced a sell off. Yet, stocks of companies engaged in the search for a COVID-19 vaccine or treatment took the news as a bullish signal. Inovio Pharmaceuticals (INO) skyrocketed over 100% this week, after the coronavirus vaccine maker disclosed it had been given $71 million by the U.S. Department of Defense (DOD). This will go toward the manufacturing of its Cellectra 3PSP smart device and the purchase of Cellectra 2000 devices. These are the devices through which Inovio’s COVID-19 DNA vaccine candidate INO-4800 is delivered into the skin.INO-4800 is currently in a Phase 1 trial with interim data expected in June. A Phase 2/3 trial of INO-4800 should also kick off in the summer.Maxim analyst Naureen Quibria argues the new contract represents vindication for Inovio’s vaccine program.“The DoD coming on board for...
CNBC recently released its 2020 Disruptor 50 list, which comprises the top 50 private companies in the world that are positioned to become the next class of multi-billion dollar giants. Landing the No. 2 spot on CNBC's Disruptor 50 list was Coupang, a $9 billion e-commerce company widely considered the "Amazon of South Korea." Its placement on the list has many asking the question: Should I invest in Coupang?Source: Michael Vi / Shutterstock.com Rumors are swirling that this innovative, hyper-growth e-commerce giant will IPO sometime in 2021. For public investors, that's exciting, because it gives us the chance to invest in Coupang, which is arguably the most explosive e-commerce company in the world today with huge upside potential in the long run.Coupang's valuation currently sits around $9 billion. The company will likely IPO at a higher valuation, maybe around $20 billion or more. Long-term, though, this is a $50+ billion company...
Stocks closed out Friday’s session sharply lower after Texas and Florida partly reversed their reopenings as a result of soaring COVID-19 infections....
